Please upgrade your browser.
Read about Argos Therapeutics Inc.'s ADAPT study and immunotherapy development, presented at our annual symposium in Chicago.
Another way to support kidney cancer research is by making a donation at http://kidneycancer.org.
To examine cancer-specific mortality in patients with nodal metastases relative to patients without nodal involvement at nephrectomy for non-metastatic renal cell carcinoma in a population-based cohort.
Any queries regarding Karen O'Sullivan's breakthrough drug for people living with kidney cancer should contact the Austin Hospital on: 03 9496 5000
PSU Football players raise funds to support the Kidney Cancer Association.
Argos Therapeutics' Phase 3 ADAPT Study for AGS-003 Highlighted During 11th Annual International Kidney Cancer Symposium
Approximately 70 North American Sites Are in Process and Enrollment Will Commence During Fourth Quarter 2012.
AVEO Oncologyâs (Nasdaq: AVEO) shares dropped more than 7 percent Monday morning, on news the stock was downgraded by Boston life sciences investment bank, Leerink Swann.
KCA has sponsored more kidney cancer research projects than any organization of its size in the world. In its most recent fiscal year, KCA invested more than $650,000 in research-related program activities.
Lynch syndrome and inherited polyposis syndromes are caused by genetic mutations that run in families and can increase your lifetime chance of getting colorectal cancer to 80% or higher.
This randomized phase II trial is studying different combinations of bevacizumab, temsirolimus, and sorafenib to see how well they work compared with bevacizumab alone in treating patients with metastatic kidney cancer.
|Powered by NeonCRM|